Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 10c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 10c, Revenues Miss

Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 5, 2020 4:02 PM EST

Experienced Biotech Executive, Patrick Machado, Joins Xenons Board of Directors

Conference Call at 4:30 pm ET Today

BURNABY, British Columbia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today reported financial results for its third quarter ended September 30, 2020 and provided a corporate update.

Dr. Simon Pimstone, Xenons Chief Executive Officer, said, We continue to make good progress as we advance our proprietary neurology product candidates into mid- to... More